MERIDEE MCARTHUR: Open Payments
NPI 1447629837 · CALHOUN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,341 in 119 payments from 17 companies in 2025. Trend: 2023 $1,317 · 2024 $2,614 · 2025 $2,341
Food & beverage: $2,341
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $473 |
| ABBVIE INC. | 41 | $458 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $243 |
| Teva Pharmaceuticals USA, Inc. | 5 | $198 |
| Otsuka America Pharmaceutical, Inc. | 5 | $194 |
| Axsome Therapeutics, Inc. | 6 | $167 |
| Noven Therapeutics, LLC | 4 | $77 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $65 |
| Alkermes, Inc. | 3 | $63 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, UZEDY, Auvelity, REXULTI, Xelstrym, INVEGA SUSTENNA.
Industry payments across GA — which companies pay providers there.
